Chronic Traumatic Encephalopathy is a progressive neurodegenerative disease associated with repetitive traumatic brain injury (TBI), most commonly seen in contact sport athletes and military veterans. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.
Chronic Traumatic Encephalopathy (CTE) is a progressive neurodegenerative disease caused by repetitive traumatic brain injury (TBI), most commonly associated with contact sports, military service, and physical abuse. CTE is characterized by the accumulation of hyperphosphorylated tau (p-tau) protein in the form of neurofibrillary tangles (NFTs), predominantly affecting cortical neurons and leading to progressive cognitive, behavioral, and motor impairments.
¶ Epidemiology and Risk Factors
CTE has been predominantly identified in individuals with a history of repetitive mild traumatic brain injuries:
- Contact sport athletes: American football players, boxers, hockey players, soccer players, and rugby players show the highest prevalence
- Military veterans: Those exposed to blast injuries and repetitive concussive events
- Physical abuse victims: Individuals with a history of repeated head trauma
The disease typically manifests decades after the period of repetitive brain trauma, with onset usually occurring in middle to late adulthood. A 2017 study of 202 former American football players found CTE in 177 (87%) of brains donated to the CTE Center at Boston University.
- Duration of exposure: Number of years participating in contact sports
- Number of concussions: Total lifetime concussive and subconcussive impacts
- Age of first exposure: Earlier age of initial head trauma exposure correlates with worse outcomes
- Genetic factors: APOE ε4 allele may increase susceptibility
CTE is defined pathologically by the presence of hyperphosphorylated tau protein NFTs in a pattern distinct from other tauopathies:
- Distribution: Initially affects the superficial cortical layers (II-III), then spreads to deeper layers
- Regional pattern: Preferentially affects frontal and temporal cortices, with relative sparing of the hippocampus early in disease
- Perivascular pattern: p-tau aggregates around blood vessels, particularly in the depths of cortical sulci
- Neuronal preference: Affects neurons preferentially over glial cells, unlike chronic traumatic encephalomyelopathy
- Astrocytic tau: Astrocytic tau pathology is a characteristic feature
flowchart TD
A["Repetitive TBI"] --> B["Subconcussive Impacts"]
B --> C["Axonal Injury"]
C --> D["Tau Protein Misfolding"]
D --> E["Hyperphosphorylation"]
E --> F["Neurofibrillary Tangle Formation"]
F --> G["Neuronal Dysfunction"]
G --> H["Cognitive Decline"]
G --> I["Behavioral Changes"]
G --> J["Motor Symptoms"]
- Axonal damage: Mechanical disruption of microtubules leads to impaired axonal transport
- Neuroinflammation: Chronic microglial activation and neuroinflammation
- Blood-brain barrier disruption: Increased permeability following repeated injuries
- Tau kinases activation: Chronic activation of GSK-3β, CDK5, and MAPK pathways
- Oxidative stress: Increased reactive oxygen species generation following repeated injuries
- Excitotoxicity: Release of excitatory neurotransmitters leads to calcium influx and neuronal dysfunction
While CTE is primarily a tauopathy, approximately 20-50% of CTE cases also show co-existing amyloid-beta plaques, similar to Alzheimer's disease. This overlap suggests common pathogenic mechanisms or that repetitive brain trauma may accelerate Alzheimer's-type pathology in susceptible individuals.
CTE symptoms typically develop years to decades after the period of repetitive brain trauma:
| Stage |
Symptoms |
| Stage I |
Headache, attention deficits, irritability, mood changes |
| Stage II |
Memory loss, impulsivity, aggression, anxiety |
| Stage III |
Severe memory loss, parkinsonism, speech abnormalities |
| Stage IV |
Dementia, severe motor impairment, psychosis |
- Memory loss and difficulty forming new memories
- Executive dysfunction and impaired judgment
- Attention and concentration deficits
- Progressive dementia
- Mood swings and irritability
- Depression and anxiety
- Impulse control problems
- Aggression and explosive temper
- Suicidal ideation
- Parkinsonism and gait disturbances
- Dysarthria (slurred speech)
- Muscle weakness and atrophy
- Tremor and rigidity
- Chronic traumatic encephalomyelopathy (CTEM): Combined tau and motor neuron pathology
- Progressive dysphagia (difficulty swallowing)
- Sleep disturbances including REM sleep behavior disorder
Currently, CTE can only be diagnosed definitively at autopsy. Proposed clinical criteria include:
- History: Documented exposure to repetitive brain trauma
- Core clinical features: Progressive cognitive/behavioral/motor impairment
- Red flags: Psychiatric symptoms, headache, sensory changes
- Neurofilament light chain (NfL): Elevated in CSF and blood
- Tau species: Total tau and phosphorylated tau in CSF
- PET imaging: Tau ligands (e.g., [^18F]AV-1451) showing characteristic patterns
- Neuroimaging: MR spectroscopy showing reduced N-acetylaspartate
- Alzheimer's disease
- Frontotemporal dementia
- Parkinson's disease
- Progressive supranuclear palsy
- Corticobasal degeneration
- Amyotrophic lateral sclerosis (when co-occurring)
There is no disease-modifying therapy for CTE. Management focuses on symptom relief:
Cognitive/Behavioral:
- Acetylcholinesterase inhibitors (donepezil, rivastigmine)
- Memantine for cognitive symptoms
- Selective serotonin reuptake inhibitors (SSRIs) for depression
- Antipsychotics for severe behavioral disturbances
Motor Symptoms:
- Levodopa for parkinsonism
- Physical therapy
- Speech therapy for dysarthria
- Rule changes: Reducing head-to-head contact in sports
- Equipment: Improved helmets and mouthguards
- Technique: Teaching proper tackling and heading techniques
- Return-to-play protocols: Strict concussion management
- Limiting exposure: Reducing contact sport participation in youth
¶ Research and Clinical Trials
- Biomarker development: Identifying in vivo diagnostic markers
- Neuropathology: Characterizing CTE staging and variants
- Genetic susceptibility: Identifying risk genes (e.g., APOE ε4)
- Therapeutic targets: Developing disease-modifying treatments
| Center |
Location |
| BU CTE Center |
Boston University |
| VA-BU-CLF Brain Bank |
Boston, MA |
| NIH CTE Program |
National Institutes of Health |
- Tau immunotherapy: Active and passive immunization against tau
- Tau aggregation inhibitors: Small molecules targeting p-tau formation
- Neuroprotective agents: Compounds promoting neuronal survival
- Anti-inflammatory therapies: Targeting chronic neuroinflammation
- Tau Pathology
- Neuroinflammation
- Axonal Transport Defects
- Traumatic Brain Injury Mechanisms
- Prefrontal Cortex - Early affected region
- Locus Coeruleus - Noradrenergic dysfunction
- Cerebral Cortex - Core affected region
- McKee et al., The spectrum of disease in chronic traumatic encephalopathy (2013). Brain. 2013;136(Pt 1):43-64.
- Mez et al., Clinicopathological Evaluation of CTE in Players of American Football (2017). JAMA. 2017;318(4):360-370.
- Stein et al., Chronic traumatic encephalopathy: a spectrum of neuropathological changes (2014). Acta Neuropathol. 2014;127(1):13-15.
- Stern et al., Clinical Presentation of CTE (2013). Neurology. 2013;81(13):1122-1129.
- Turner et al., Defining the Spectrum of Long-Term sequelae (2021)